This is a working overview of pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also dissolves in common polar solvents |
| Storage temperature | Minus 20 degrees Celsius or lower | Applies to dry powder, desiccated and dark |
| Typical analytical methods | Reversed-phase HPLC and mass spectrometry | Used together for purity and identity |
| Primary degradation route | Hydrolysis and aggregation | No cysteine present, so disulfide formation is unlikely |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Epidermolysis bullosa dystrophica or dystrophic EB (DEB) is an inherited disease affecting the skin and other organs. "Butterfly child" is the colloquial name for children born with the disease, as their skin is seen to be as delicate and fragile as the wings of a butterfly.
=== 1.2a === DisplayPort version 1.2a was released in January 2013 and may optionally include VESA's Adaptive Sync. AMD's FreeSync uses the DisplayPort Adaptive-Sync feature for operation. FreeSync was first demonstrated at CES 2014 on a Toshiba Satellite laptop by making use of the Panel-Self-Refresh (PSR) feature from the Embedded DisplayPort standard, and after a proposal from AMD, VESA later adapted the Panel-Self-Refresh feature for use in standalone displays and added it as an optional feature of the main DisplayPort standard under the name "Adaptive-Sync" in version 1.2a. As it is an optional feature, support for Adaptive-Sync is not required for a display to be DisplayPort 1.2a-compliant.
== Contraindication for specific diseases == Aminoglycosides can exacerbate weakness in patients with myasthenia gravis, and use is therefore avoided in these patients. Aminoglycosides are contraindicated in patients with mitochondrial diseases as they may result in impaired mtDNA translation, which can lead to irreversible hearing loss, tinnitus, cardiac toxicity, and renal toxicity. However, hearing loss and tinnitus have also been observed in some patients without mitochondrial diseases.
== Further reading == Jung, Hans Joachim (2000). Panzer Soldiers for "God, Honor and Fatherland": The History of Panzerregiment Grossdeutschland. Winnipeg, Canada: J. J. Fedorowicz. ISBN 0-921991-51-7. Herbst, Jurgen (2002). Requiem for a German Past: A Boyhood among the Nazis. Madison, Wisconsin: University of Wisconsin Press. ISBN 978-0-299-16414-0. de Lannoy, François; Perrigault, Jean-Claude (1998). La Grossdeutschland: du régiment au Panzerkorps, 1939–1945 [Grossdeutschland: From Regiment to Panzer Corps 1939–1945] (in French). Bayeux, France: Heimdal. ISBN 2-84048-110-3. Lucas, James (1978). Germany's Elite Panzer Force: Grossdeutschland. London: Macdonald and Jane's. ISBN 0-35401-165-0. McGuirl, Thomas; Spezzano, Remy (1997). God, Honor, Fatherland: A Photo History of Panzergrenadier Division Grossdeutschland on the Eastern Front 1942 - 1944. Connecticut: Southbury. ISBN 0-9657584-0-0. Novotny, Alfred (2002). The Good Soldier: From Austrian Social Democracy to Communist Captivity with a Soldier of Panzer-Grenadier Division Grossdeutschland. Bedford, Pennsylvania: Aberjona Press. ISBN 0-966638-99-9. Quarrie, Bruce (1977). Panzer-Grenadier Division Grossdeutschland. London: Osprey Publishing Group. ISBN 0-85045-055-1.
== Symptoms and signs == Symptoms associated with cardiac myxomas are typically due to the effect of the mass of the tumor obstructing the normal flow of blood within the chambers of the heart. Because pedunculated myxomas are somewhat mobile, symptoms may only occur when the patient is in a particular position. Some symptoms of myxoma may be associated with the release of interleukin 6 (IL-6) by the myxoma. High levels of IL-6 may be associated with a higher risk of embolism of the myxoma. Symptoms of a cardiac myxoma include:
Sources: en.wikipedia.org
Darmstadtium has no stable or naturally occurring isotopes. Several radioactive isotopes have been synthesized in the laboratory, either by fusing two atoms or by observing the decay of heavier elements. Eleven different isotopes of darmstadtium have been reported with atomic masses 267, 269–271, 273, 275–277, and 279–281, although darmstadtium-267 is unconfirmed. Three darmstadtium isotopes, darmstadtium-270, darmstadtium-271, and darmstadtium-281, have known metastable states, although that of darmstadtium-281 is unconfirmed. Most of these decay predominantly through alpha decay, but some undergo spontaneous fission.
=== Biology and medicine === Abductor digiti minimi muscle of hand Adrenomedullin, a vasodilator peptide hormone Acinar-to-ductal metaplasia, a condition affecting pancreatic cells (see Acinar cell § Acinar-to-ductal metaplasia)
=== Jonathan: The Rollerblade Bully === First aired 12 April 2009 Mayhem Miller helps Sergio and Thomas with Jonathan, a self-proclaimed "aggressive in-line skater," who thinks he has the right to pick on weaker people in the neighborhood, by putting him in the ring with MMA champion Jake Shields to teach him a lesson he won't soon forget.
In the blockchain, bitcoins are linked to specific strings called addresses. Most often, an address encodes a hash of a single public key. Creating such an address involves generating a random private key and then computing the corresponding address. This process is almost instant, but the reverse (finding the private key for a given address) is nearly impossible. Publishing such a bitcoin address does not risk its private key, and it is extremely unlikely to accidentally generate a used key with funds. To use bitcoins, owners need their private key to digitally sign transactions, which are verified by the network using the public key, keeping the private key secret. An address may encode the hash of a bitcoin script that specifies more complex requirements to spend the funds. One common example is "multisig", in which multiple distinct private keys must mutually sign any transaction that attempts to spend the funds. Bitcoin transactions use a Forth-like scripting language, involving one or more inputs and outputs. When sending bitcoins, a user specifies the recipients' addresses and the amount for each output. This allows sending bitcoins to several recipients in a single transaction. To prevent double-spending, each input must refer to a previous unspent output in the blockchain. Using multiple inputs is similar to using multiple coins in a cash transaction. As in a cash transaction, the sum of inputs can exceed the intended sum of payments. In such a case, an additional output can return the change back to the payer.
Major Crispin Nicholas Black (511814), Welsh Guards. Major Alexander Thomas Boyd (496287), The Royal Logistic Corps. Major Joseph Bright (518051), Adjutant General's Corps (SPS). 24652448 Sergeant (Acting Staff Sergeant) David William Brown, The Royal Logistic Corps. Major Malcolm Hugh Peter Buchanan (495490), The Royal Logistic Corps. 24330851 Warrant Officer Class 1 Andrew Kenneth George Card, The Royal Logistic Corps. Major Steven Cheetham, , (495676), Corps of Royal Engineers (Volunteers), Territorial Army. Acting Lieutenant Colonel John Cobb (448934), Stonyhurst College Combined Cadet Force, Territorial Army. Major Gavin Terence Collinson (501572), The Royal Logistic Corps. 24563002 Staff Sergeant Anthony Raymond Cooper, Adjutant General's Corps (RMP). 24185755 Warrant Officer Class 1 Alan John Crawford, Scots Guards. 24198806 Warrant Officer Class 1 William Crook, Adjutant General's Corps (SPS). 23962020 Staff Sergeant Graham Stuart Daniell, Corps of Royal Electrical and Mechanical Engineers. 24511850 Sergeant (Acting Colour Sergeant) Stephen Denham, The Worcestershire and Sherwood Foresters Regiment. 24072935 Staff Sergeant John James Flannigan, The Light Dragoons. Captain John William Alexander France, , (508406), The Green Howards (Volunteers), Territorial Army. 24750683 Corporal Michael Sean Gill, Corps of Royal Engineers. Major Richard Duncan Brownrigg Gordon (513813), Adjutant General's Corps (ETS). Major Paul Anthony Philip Griffiths (517124) Royal Regiment of Artillery. Captain (Queen's Gurkha Officer) Dharmendra Gurung (537028), The Royal Gurkha Rifles.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.
Cold, dry, and dark conditions are standard, typically at or below minus twenty degrees Celsius for long-term holding. Vials are usually warmed to room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is generally avoided.
This depends on pH, buffer, and concentration, with acidic conditions often reported as more favorable. Hydrolysis accelerates at room temperature, so solutions are commonly prepared fresh or stored frozen in single-use aliquots. No single shelf life applies across formulations.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.